Stella Chemifa Of Japan To Commercialize Boron Isotope Cancer Treatment System
This article was originally published in PharmAsia News
Osaka-based Stella Chemifa plans to commercialize its boron neutron capture treatment by 2011. BNCT uses neutron rays to radiate cancer tissues embedded with boron isotope chemical, and selectively kill cancer cells. By only destroying targeted cells and having no impact to other cells, BNCT can be used to treat malignant cancers such as brain tumors, mesothelioma, lung and liver cancer. Starting in 2009, clinical trials will be conducted jointly with Kyodo University's Research Reactor Institute. (Click here for more - Japanese language
You may also be interested in...
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.